Last reviewed · How we verify

IPX203 ER CD-LD — Competitive Intelligence Brief

IPX203 ER CD-LD (IPX203 ER CD-LD) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopaminergic agent; levodopa/carbidopa combination. Area: Neurology.

phase 3 Dopaminergic agent; levodopa/carbidopa combination Dopamine pathway; aromatic L-amino acid decarboxylase inhibition Neurology Small molecule Live · refreshed every 30 min

Target snapshot

IPX203 ER CD-LD (IPX203 ER CD-LD) — Impax Laboratories, LLC. IPX203 ER CD-LD is a combination extended-release formulation of carbidopa and levodopa designed to provide sustained dopaminergic replacement therapy for Parkinson's disease with reduced dosing frequency.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
IPX203 ER CD-LD TARGET IPX203 ER CD-LD Impax Laboratories, LLC phase 3 Dopaminergic agent; levodopa/carbidopa combination Dopamine pathway; aromatic L-amino acid decarboxylase inhibition

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopaminergic agent; levodopa/carbidopa combination class)

  1. Impax Laboratories, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IPX203 ER CD-LD — Competitive Intelligence Brief. https://druglandscape.com/ci/ipx203-er-cd-ld. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: